TataMD, Anderson Diagnostic Labs Partner To Detect New COVID- 19 Variants

Mumbai : Tata Medical and Diagnostics has entered into a clinical collaboration with city-based Anderson Diagnostics and Labs to detect new COVID-19 variants from the U.K., Brazil and Africa with the indigenously developed TataMD CHECK – diagnostic kit, the company said on Monday.

The Indian Council of Medical Research approved diagnostic kit, which has already conducted over 10,000 COVID-19 tests, can be scaled rapidly, TataMD, which is the health care venture of the Tata Group, said in a release.

“…the indigenously developed TataMD CHECK offers a clear, quicker and more accessible alternative to RT-PCR (tests).

Our clinical partnership with Tata MD will help support the transformation of COVID testing to arrest the emergence of a second wave in India,” Anderson Diagnostics and Labs director, Dr Srinivasaraman said.

Anderson Diagnostics MD Dr Anand Krishnamoorthy said, “having tested and validated more than 10,000 samples, we feel this technology is on par in the world and futuristic.”

The partnership between TataMD and Anderson Diagnostics would act as an enabler to optimise delivery of the COVID19 tests, advance diagnosis for emerging pandemic, create more value for the people, the release said.

“Working with the exceptional team at Anderson Diagnostics has demonstrated the impact that a new technology-based product like TataMD CHECK can have on strengthening our COVID-19 testing capacity and access to testing in remote areas”, Tata Medical and Diagnostics, MD, Girish Krishnamurthy said.

Tata’s clinical collaboration with Anderson Diagnostics will only drive advances in the diagnostic space including fast detection of new variants of COVID-19 as the pandemic continues, he added.

  • Related Posts

    PGIMS recalls drug amid probe into deaths

    The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PGIMS recalls drug amid probe into deaths

    PGIMS recalls drug amid probe into deaths

    NPPA list brings little relief: No price cut for 25% cancer drugs

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    For Aakash Healthcare, Community People are Apples of its Eyes

    For Aakash Healthcare, Community People are Apples of its Eyes

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Yashoda Medicity: Baby takes a Giant Step in just One Year

    Yashoda Medicity: Baby takes a Giant Step in just One Year